Another line of evidence for the role of chromatin remodeling in paving the way for NFκB-driven cancer progression comes from glioblastoma, where NFκB selectively drives the expression of EZH2 by activating its transcription; then, the final protein product, EZH2, once activated, causes a genome-wide change in methylated histone H3K27me3 expression and distribution. This evidence concerns the gene NFKB1 and cancer.